Last reviewed · How we verify
Sodium Hyaluronate
Sodium Hyaluronate is a Artificial tear / ocular lubricant Small molecule drug developed by Tianjin Eye Hospital. It is currently FDA-approved for Dry eye disease / keratoconjunctivitis sicca, Ocular surface lubrication and protection. Also known as: hyaluronate, Hyalgan, hyaluronic acid, HA35.
Sodium hyaluronate acts as a lubricant and humectant that retains moisture on the ocular surface to relieve dry eye symptoms.
Sodium hyaluronate is used in various medical treatments, including eyedrops for conditions such as glaucoma and corneal de-epithelialization, as well as injections for conditions like cellulite of the buttocks. It has been studied in clinical trials for its effects on optical coherence tomography imaging quality, among other uses.
At a glance
| Generic name | Sodium Hyaluronate |
|---|---|
| Also known as | hyaluronate, Hyalgan, hyaluronic acid, HA35, hyalgan |
| Sponsor | Tianjin Eye Hospital |
| Drug class | Artificial tear / ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium hyaluronate is a naturally occurring polysaccharide that binds water molecules and forms a protective, hydrating film on the cornea and conjunctiva. It reduces friction between the eyelid and ocular surface while maintaining corneal hydration, thereby alleviating discomfort and promoting epithelial healing in dry eye disease.
Approved indications
- Dry eye disease / keratoconjunctivitis sicca
- Ocular surface lubrication and protection
Common side effects
- Transient blurred vision
- Eye irritation or discomfort
- Mild conjunctival hyperemia
Key clinical trials
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Clinical Investigation on Lips Treated With HA-filler (NA)
- Using Different Biomaterials to Preserve Bone After Tooth Extraction (NA)
- Hyaluronic Acid and Albumin-PRF in Non-Surgical Periodontal Therapy (NA)
- Early vs Delayed Intravesical Blad-Care During BCG Therapy (NA)
- A Clinical Investigation of the Decoria® Aesthetic Group (DAG) for Correction of Nasolabial Folds (NLF) (NA)
- Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Hyaluronate CI brief — competitive landscape report
- Sodium Hyaluronate updates RSS · CI watch RSS
- Tianjin Eye Hospital portfolio CI
Frequently asked questions about Sodium Hyaluronate
What is Sodium Hyaluronate?
How does Sodium Hyaluronate work?
What is Sodium Hyaluronate used for?
Who makes Sodium Hyaluronate?
Is Sodium Hyaluronate also known as anything else?
What drug class is Sodium Hyaluronate in?
What development phase is Sodium Hyaluronate in?
What are the side effects of Sodium Hyaluronate?
Related
- Drug class: All Artificial tear / ocular lubricant drugs
- Manufacturer: Tianjin Eye Hospital — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease / keratoconjunctivitis sicca
- Indication: Drugs for Ocular surface lubrication and protection
- Also known as: hyaluronate, Hyalgan, hyaluronic acid, HA35, hyalgan
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing